Abbott has agreed to pay approximately $670 million to resolve the Gill case and claims from around 2,000 other individuals concerning its specialty formulas for preterm infants. This settlement avoids further appeals and potential higher costs associated with the initial $495 million verdict, providing clarity on a significant legal liability.
Abbott has reached a settlement totaling approximately $670 million to resolve the Gill case, which initially resulted in a $495 million verdict against the company, and claims from about 2,000 other individuals related to its preterm infant formulas. This settlement, while substantial, provides a definitive resolution to a major legal overhang, preventing further protracted appeals and potentially higher costs from accrued interest on the original judgment. For traders, this removes a significant uncertainty for ABT, as the company can now move past this liability. The short-term impact is a large cash outflow, but the long-term implication is the removal of a legal cloud, which could be seen as a positive for investor confidence.